0.43Open0.50Pre Close11 Volume902 Open Interest3.00Strike Price470.00Turnover69.47%IV6.92%PremiumNov 15, 2024Expiry Date0.18Intrinsic Value100Multiplier18DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type0.6790Delta0.7196Gamma10.60Leverage Ratio-0.0051Theta0.0009Rho7.20Eff Leverage0.0026Vega
Verastem Stock Discussion
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
Verastem Oncology (VSTM) announced the acceptance of a late-breaking abstract for oral presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting in October 2024. The presentation will feature mature data from the Phase 2 RAMP 201 clinical trial, evaluating the combination of avutometinib (RAF/MEK ...
No comment yet